RESUMO
Allergic conjunctivitis is an increasingly frequent condition with a higher prevalence in children. It can be debilitating and is responsible for a great economic burden. These guidelines were developed on the basis of the medical literature (PubMed/Medline database) and the experience of an Expert Committee composed of members of the Brazilian Society of Pediatric Ophthalmology, the Brazilian Council of Ophthalmology, the Brazilian Society of Pediatrics, and the Brazilian Association of Allergy and Immunology. Allergic conjunctivitis is considered to be controlled when the ocular symptoms are not uncomfortable or are present, at most, on 2 days a week; the visual analog scale score is below 5; and the degree of conjunctival hyperemia is graded 0 or 1 on the Efron scale. Allergic conjunctivitis should be classified as mild, moderate, severe, and vision-threatening for adequate treatment and monitoring of frequency. The present document is a guideline for diagnosing, treating, and monitoring pediatric allergic conjunctivitis considering the clinical and demographic aspects of allergic conditions in Brazil.
Assuntos
Conjuntivite Alérgica , Brasil , Criança , Conjuntivite Alérgica/tratamento farmacológico , Conjuntivite Alérgica/terapia , Humanos , PrevalênciaRESUMO
BACKGROUND: In spite of allergen-specific immunotherapy (SIT) multiple benefits, its use is restricted in some countries owing to concerns about severe adverse reactions. OBJECTIVE: To evaluate systemic adverse reactions in patients with atopic dermatitis, allergic asthma, allergic rhinitis and allergic conjunctivitis who received subcutaneous immunotherapy with tyrosine-adsorbed Dermatophagoides and Glycyphagoides dust mites extracts. METHODS: Retrospective study of the 2010-2015-period that included 773 patients diagnosed with IgE-mediated diseases, where the safety of allergen-specific immunotherapy was described according to the World Organization of Allergy subcutaneous immunotherapy-induced systemic reactions classification system. RESULTS: 79.7 % of patients had rhinitis, 54.9 % asthma, 34.5 % conjunctivitis and 16.4 % atopic dermatitis. Out of 12,546 tyrosine-adsorbed extract doses, 45 systemic reactions were recorded: 12 were grade 1 (30 %), 27 grade 2 (67.5 %) and 1 was grade 3 (2.5 %); the reaction rate was 0.35 per 100 administered injections, for an incidence rate of 5.8 %. No fatal reactions occurred. CONCLUSION: The frequency of systemic reactions with subcutaneous immunotherapy with Dermatophagoides farinae, Dermatophagoides pteronyssinus and Blomia tropicalis tyrosine-adsorbed extracts was similar to that reported with other extracts.
Antecedentes: Pese a los múltiples beneficios de la inmunoterapia alérgeno-específica, en algunos países se restringe su uso por temor a las reacciones adversas severas. Objetivo: Evaluar las reacciones sistémicas adversas en pacientes con dermatitis atópica, asma, rinitis y conjuntivitis alérgicas, que recibieron inmunoterapia subcutánea con extractos tirosinados para ácaros Dermatophagoides y Glycyphagoides. Métodos: Estudio retrospectivo del periodo 2010-2015 en el que se incluyó a 773 pacientes con diagnóstico de enfermedades mediadas por IgE. Se describió la seguridad de la inmunoterapia alérgeno-específica conforme al sistema de clasificación de las reacciones sistémicas con inmunoterapias subcutánea de la Organización Mundial de Alergias. Resultados: 79.7 % de los pacientes presentó rinitis, 54.9 % asma, 34.5 % conjuntivitis y 16.4 % dermatitis atópica. De 12 546 dosis subcutánea con extractos tirosinados se registraron 45 reacciones sistémicas: 12 grado 1 (30 %), 27 de grado 2 (67.5 %) y 1 grado 3 (2.5 %); la tasa de reacción fue de 0.35 por cada 100 inyecciones administradas, que representó una incidencia de 5.8 %. No se registraron reacciones fatales. Conclusión: Con la inmunoterapia subcutánea con extractos tirosinados de Dermatophagoides farinae, Dermatophagoides pteronyssinus y Blomia tropicalis se presentó una frecuencia de reacciones sistémicas similar a la informada con otros extractos.
Assuntos
Antígenos de Dermatophagoides/efeitos adversos , Dessensibilização Imunológica/efeitos adversos , Adolescente , Adsorção , Animais , Antígenos de Dermatophagoides/administração & dosagem , Antígenos de Dermatophagoides/química , Antígenos de Dermatophagoides/uso terapêutico , Asma/terapia , Criança , Pré-Escolar , Conjuntivite Alérgica/terapia , Dermatite Atópica/terapia , Dermatophagoides pteronyssinus/imunologia , Relação Dose-Resposta Imunológica , Feminino , Humanos , Masculino , Estudos Retrospectivos , Rinite/terapia , TirosinaRESUMO
ABSTRACT Purpose: To evaluate the long-term outcomes of medically or surgically treated patients with atopic keratoconjunctivitis (AKC). Methods: Charts of 16 patients with AKC (32 eyes) observed between 1996 and 2013 were reviewed retrospectively. Outcome measures included demographic features, follow-up duration, and biomicroscopic findings at the first and most recent visits. The corrected distance visual acuity (CDVA; in decimal units) was evaluated at the initial visit and the 1-, 6-, and 12-month follow-up visits. Results: In the medically treated group (25 eyes of 15 patients), the median follow-up duration was 3 (range, 1-9) years, and the median CDVA values were 0.01 (0.001-1.0) at the first visit and 0.01 (0.001-0.8) at the most recent visit (p=0.916). In the penetrating keratoplasty (PK) group (7 eyes of 6 patients), the median follow-up duration was 7 years (range, 1-11), and the median CDVA increased from 0.01 (0.001-0.01) to 0.2 (0.001-0.7) postoperatively (p=0.043). Conclusion: Whereas most AKC patients maintained a useful CDVA with medical treatment, PK may be required in some cases. Despite the frequent occurrence of complications, PK can significantly improve the CDVA.
RESUMO Objetivo: Avaliar os resultados a longo prazo em ceratoconjuntivite atópica (AKC) pacientes que foram tratados clinicamente ou cirurgicamente. Métodos: Os prontuários de 16 pacientes (32 olhos) com AKC, que foram acompanhados entre 1996 e 2013 foram avaliados retrospectivamente. As medidas adotadas foram as características demográficas, tempos de seguimento, e resultados biomicroscópicos da visita inicial e da visita mais recente. A acuidade visual corrigida para distância (CDVA), apresentada em unidades decimais, foi avaliada na visita inicial e nas visitas do 1º mês, 6º mês e 1º ano de seguimento. Resultados: No grupo tratado clinicamente (25 olhos de 15 pacientes), a mediana do tempo de seguimento foi de 3 anos (variação, 1-9) e a CDVA média foi de 0,01 (0,001-1,0) na visita inicial e 0,01 (0,001-0,8) na visita mais recente (p=0,916). No grupo de ceratoplastia penetrante (PK) (7 olhos de 6 pacientes), a mediana de tempo de seguimento foi de 7 anos (variação, 1-11) e a CDVA média aumentou de 0,01 (0,001-0,01) para 0,2 (0,001-0,7) (p=0,043) no pós-operatório. Conclusões: Embora a maioria dos pacientes AKC mantém a CDVA útil com o tratamento clínico, alguns necessitam de PK a fim de obter CDVA útil. Embora as complicações pós-PK ocorrem com freqüência, a CDVA pode melhorar significativamente.
Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto , Idoso , Adulto Jovem , Conjuntivite Alérgica/terapia , Acuidade Visual/fisiologia , Ceratoplastia Penetrante , Ceratoconjuntivite/terapia , Conjuntivite Alérgica/cirurgia , Estudos de Casos e Controles , Estudos Retrospectivos , Seguimentos , Resultado do Tratamento , Avaliação de Resultados em Cuidados de Saúde , Ceratoconjuntivite/cirurgiaRESUMO
PURPOSE:: To evaluate the long-term outcomes of medically or surgically treated patients with atopic keratoconjunctivitis (AKC). METHODS:: Charts of 16 patients with AKC (32 eyes) observed between 1996 and 2013 were reviewed retrospectively. Outcome measures included demographic features, follow-up duration, and biomicroscopic findings at the first and most recent visits. The corrected distance visual acuity (CDVA; in decimal units) was evaluated at the initial visit and the 1-, 6-, and 12-month follow-up visits. RESULTS:: In the medically treated group (25 eyes of 15 patients), the median follow-up duration was 3 (range, 1-9) years, and the median CDVA values were 0.01 (0.001-1.0) at the first visit and 0.01 (0.001-0.8) at the most recent visit (p=0.916). In the penetrating keratoplasty (PK) group (7 eyes of 6 patients), the median follow-up duration was 7 years (range, 1-11), and the median CDVA increased from 0.01 (0.001-0.01) to 0.2 (0.001-0.7) postoperatively (p=0.043). CONCLUSION:: Whereas most AKC patients maintained a useful CDVA with medical treatment, PK may be required in some cases. Despite the frequent occurrence of complications, PK can significantly improve the CDVA.
Assuntos
Conjuntivite Alérgica/terapia , Ceratoconjuntivite/terapia , Ceratoplastia Penetrante , Acuidade Visual/fisiologia , Adolescente , Adulto , Idoso , Estudos de Casos e Controles , Conjuntivite Alérgica/cirurgia , Feminino , Seguimentos , Humanos , Ceratoconjuntivite/cirurgia , Masculino , Pessoa de Meia-Idade , Avaliação de Resultados em Cuidados de Saúde , Estudos Retrospectivos , Resultado do Tratamento , Adulto JovemRESUMO
BACKGROUND: Allergen immunotherapy has demonstrated usefulness in the management of allergic diseases such as asthma, allergic rhinitis and conjunctivitis. However, little is known about its effectiveness in vernal keratoconjunctivitis (VKC), a disease mediated by IgE and lymphocytes, that can cause loss of visual acuity in a permanent way. OBJECTIVE: To describe safety and effectiveness of allergen immunotherapy in a group of patients with VKC. METHODS: From a sample of 575 patients sensitized to house dust mites, who received ultra-rush immunotherapy for asthma, allergic rhinoconjuctivitis or atopic dermatitis, 28 patients with VKC were selected and a retrospective analysis was performed with the evaluation of factors related to safety, pharmacological treatment and clinical response to immunotherapy.. RESULTS: Twenty eight patients with VKC who received allergen immunotherapy were studied. There were 21 men and 7 women, with an average age of 11 years. A total of 490 doses were administered (35 for build-up and 455 for maintenance) for different periods. The average number of doses per patient was 17. There were no local or systemic reactions. Seventy one percent of the patients presented a clear reduction in the use of medications, with an improvement in symptoms 89% and physical findings 68%. CONCLUSIONS: Allergen immunotherapy seems to be a safe and efficient treatment for patients with VKC, and can contribute along with pharmacological management to the improvement of symptoms and reduction in the use of medications.
Assuntos
Conjuntivite Alérgica/terapia , Dessensibilização Imunológica , Adolescente , Criança , Pré-Escolar , Feminino , Humanos , Masculino , Estudos Retrospectivos , Resultado do Tratamento , Adulto JovemRESUMO
Apresentar um tratamento homeo-pático de úlcera de córnea por ceratoconjuntivite primaveril, considerando-o bioeticamente. MÉTODOS: foram usados nove casos, encami-nhados por insucesso terapêutico convencional. Escolheram-se os medicamentos de acordo com características singularizantes dos pacientes que incluíram o psiquismo. Levantaram-se os custos medicamentosos consultando-se três farmácias homeopáticas e três não-homeopáticas de Belo Horizonte. O tratamento convencional foi estimado a partir da medicação usada pelos enfermos antes do início dos cuidados homeopáticos. RESULTADOS: as cicatrizações ocorreram entre quinze e cento e oitenta dias, com custo medicamentoso médio de oito dólares, cerca de treze vezes menor do que a estimativa de custo direto de um mês da abordagem convencional. O manejo terapêutico da similitude pode minimizar preocupações bioéticas relativas à atenção à saúde de crianças com ceratoconjuntivite primaveril. CONCLUSÕES: a homeopatia pode colaborar para o tratamento desta enfermidade, aprimorando-o bioeticamente...
Present a homeopathic treatment of corneal ulcers for vernal keratoconjunctivitis and its bioethical implications. METHODS: nine cases were studied, after having been referred following the failure of conventional treatments. Medications were chosen according to the specific characteristics of the patients, including psychiatric disorders. The medication costs were gathered by consulting three homeopathic and three non-homeopathic pharmacies in Belo Horizonte. The estimate for conventional treatment cost was based on the medication prescribed for the patient prior to the commencement of homeopathic care. RESULTS: scarring occurred between fifteen and one-hundred eighty days, with an average medication cost of eight dollars, roughly one-thirteenth of the estimated direct cost of one month of conventional treatment. The similarity of therapeutic approaches should minimize bioethical concerns regarding the medical care of children with vernal keratoconjunctivitis. CONCLUSIONS: homeopathy can contribute to both the medical and bioethical aspects of treatment of this disease...
Assuntos
Humanos , Masculino , Criança , Conjuntivite Alérgica/terapia , Homeopatia , Mecanismo de Ação do Medicamento Homeopático , Úlcera da Córnea/terapia , Bioética , Experimentação Humana , Ensaio Patogenético Homeopático , Princípio da SimilitudeRESUMO
PURPOSE: To establish current definition, classification and staging, and to develop diagnosis and treatment recommendations for ocular allergy, by using Delphi approach. METHODS: Ten Latin American experts on ocular allergy participated in a 4-round Delphi panel approach. Four surveys were constructed and answered by panelists. A two-thirds majority was defined as consensus. Definition, classification, staging and diagnosis and treatment recommendations were the main outcomes. RESULTS: "Ocular allergy" was proposed as the general term to describe ocular allergic diseases. Consensus regarding classification was not reached. Signs and symptoms were considered extremely important for the diagnosis. It was consensus that a staging system should be proposed based on the disease severity. Environmental control, avoidance of allergens and the use of artificial tears were recommended as first line treatment. The secondary treatment should include topical anti-histamines, mast cell stabilizers and multi actions drugs. Topical non-steroidal anti-inflammatory and vasoconstrictors were not recommended. Topical corticosteroids were recommended as third line of treatment for the most severe keratoconjunctivitis. Consensus was not reached regarding the use of systemic corticosteroids or immunosuppressant. Surgical approach and unconventional treatments were not recommended as routine. CONCLUSION: The task of creating guidelines for ocular allergies showed to be very complex. Many controversial topics remain unsolved. A larger consensus including experts from different groups around the world may be needed to further improve the current recommendations for several aspects of ocular allergy.
OBJETIVO: Estabelecer a definição, classificação e estadiamento e desenvolver recomendações para o diagnóstico e tratamento da alergia ocular, usando o método Delphi de consenso. MÉTODOS: Dez especialistas em alergia ocular da América Latina participaram do painel. Quatro rodadas de questionários foram respondidas pelos painelistas. Consenso foi definido quando houve 2/3 ou mais de concordância. Os aspectos principais avaliados foram: definição, classificação, estadiamento e recomendações para diagnóstico e tratamento da alergia ocular. RESULTADOS: "Alergia Ocular" foi proposto como termo geral para descrever as doenças alérgicas oculares. Consenso sobre classificação não foi atingido. Sinais e sintomas foram considerados extremamente importantes para o diagnóstico. Consenso foi atingido sobre a necessidade de se estabelecer um sistema de estadiamento baseado na gravidade da doença. Controle ambiental e de exposição a alérgenos e o uso de lágrimas artificiais foram considerados tratamento de primeira linha e o uso tópico de anti-histamínicos, estabilizadores de membranas de mastócitos e drogas de ação múltipla, como tratamento de segunda linha. Anti-inflamatórios não hormonais tópicos e vasoconstrictores não foram recomendados. Corticosteroides tópicos foram estabelecidos como terceira linha de tratamento para casos graves de ceratoconjuntivite. Consenso não foi obtido em relação ao uso sistêmico de corticosteróides e imunossupressores. Abordagem cirúrgica e tratamentos não convencionais não foram recomendados de rotina. CONCLUSÃO: O desafio de criar recomendações para diversos aspectos da alergia ocular mostrou-se muito complexo, muitos deles permanencendo ainda controversos. Consensos mais amplos podem ser necessários para melhorar as recomendações atuais referentes a importantes aspectos da alergia ocular.
Assuntos
Humanos , Conjuntivite Alérgica , Conjuntivite Alérgica/classificação , Conjuntivite Alérgica/diagnóstico , Conjuntivite Alérgica/terapia , Técnica Delphi , Diagnóstico Diferencial , América Latina , Índice de Gravidade de DoençaRESUMO
PURPOSE: To establish current definition, classification and staging, and to develop diagnosis and treatment recommendations for ocular allergy, by using Delphi approach. METHODS: Ten Latin American experts on ocular allergy participated in a 4-round Delphi panel approach. Four surveys were constructed and answered by panelists. A two-thirds majority was defined as consensus. Definition, classification, staging and diagnosis and treatment recommendations were the main outcomes. RESULTS: "Ocular allergy" was proposed as the general term to describe ocular allergic diseases. Consensus regarding classification was not reached. Signs and symptoms were considered extremely important for the diagnosis. It was consensus that a staging system should be proposed based on the disease severity. Environmental control, avoidance of allergens and the use of artificial tears were recommended as first line treatment. The secondary treatment should include topical anti-histamines, mast cell stabilizers and multi actions drugs. Topical non-steroidal anti-inflammatory and vasoconstrictors were not recommended. Topical corticosteroids were recommended as third line of treatment for the most severe keratoconjunctivitis. Consensus was not reached regarding the use of systemic corticosteroids or immunosuppressant. Surgical approach and unconventional treatments were not recommended as routine. CONCLUSION: The task of creating guidelines for ocular allergies showed to be very complex. Many controversial topics remain unsolved. A larger consensus including experts from different groups around the world may be needed to further improve the current recommendations for several aspects of ocular allergy.
Assuntos
Conjuntivite Alérgica , Conjuntivite Alérgica/classificação , Conjuntivite Alérgica/diagnóstico , Conjuntivite Alérgica/terapia , Técnica Delphi , Diagnóstico Diferencial , Humanos , América Latina , Índice de Gravidade de DoençaRESUMO
Natural rubber latex has been in widespread use for over a century. Reports of immediate hypersensitivity to latex have increased dramatically since the first case was reported in 1979, specially in persons with cumulative latex exposure. A 13 year old male was referred to our office. He had been wearing orthodontic rubber bands for two years. The previous year he started having itchy, red and watery eyes, with sneezing and runny nose when he was exposed to rubber products. Then he developed oral edema and lip ulcers. Finally, he experienced cough, wheezing, chest tightness and dyspnea. The patient had no history of undergoing surgery, and his mother denied pacifier use. He had no history of fruit and vegetables allergy. Physical examination revealed conjunctival hyperemia, with fine papillary response in the upper tarsal plate, hyaline rhinorrhea, turbinate hypertrophy and perioral ulcers. Skin prick test were positive for latex and Quercus albus. Patch test with latex glove was negative, but positive with rubber tourniquet. Total IgE was 365 UI/mL. Latex-specific IgE testing confirmed the diagnosis. Spirometric values were normal. He started rush sublingual immunotherapy with latex extract. When he had finished, he traveled abroad. At immigration the inspectors examined him with latex gloves. Immediately he developed anaphylaxis, needing urgent medical attention. Although the efficacy and safety of sublingual immunotherapy for latex allergy has been demonstrated, the most effective strategy is complete avoidance of latex-containing products. World Public Health Services must promote the use of synthetic elastomer gloves in airports worldwide.
Assuntos
Dessensibilização Imunológica , Hipersensibilidade ao Látex/terapia , Administração Sublingual , Adolescente , Anafilaxia/etiologia , Conjuntivite Alérgica/etiologia , Conjuntivite Alérgica/terapia , Dessensibilização Imunológica/métodos , Luvas Protetoras/efeitos adversos , Humanos , Hipersensibilidade ao Látex/etiologia , Masculino , Úlceras Orais/etiologia , Úlceras Orais/terapia , Aparelhos Ortodônticos/efeitos adversos , Hipersensibilidade Respiratória/etiologia , Hipersensibilidade Respiratória/terapia , Borracha/efeitos adversos , Medidas de Segurança , Viagem , Falha de TratamentoRESUMO
Allergic conjunctivitis is a group of diseases that are frequent in childhood, associated to several allergic diseases affecting the ocular surface. It is related to type 1 hypersensitivity reactions. Two acute disorders: seasonal allergic conjunctivitis and perennial allergic conjunctivitis, exist, as do three chronic diseases: vernal keratoconjunctivitis, atopic keratoconjunctivitis and giant papillary conjunctivitis. The ocular surface inflammation causes itching, tearing, lid and conjunctival edema-redness, and photophobia during the acute phase and can lead to a classic late-phase response (associated to eosinophilia and neutrophilia) in a subset of individuals. As in the case of several chronic allergic diseases, it can remodel the ocular surface tissue. This allergic disease is very frequent. Vernal keratoconjunctivitis could produce corneal lesions and visual illness; however, atopic keratoconjunctivitis does not permanently affect the vision. The aim of this review is to provide a current overview for a better understanding of the symptoms associated to this disease, to describe its classification, recent advances in its physiopathology and its treatment.